INTRODUCTION
aHUS is a rare disease that causes renal failure because of thrombosis in kidney glomeruli. 1 Most genetic forms of aHUS are caused by mutations that lead to hyperactivation of the complement system. 2 We recently showed that loss-of-function mutations in DGKE cause a novel form of aHUS that does not respond to anti-complement therapy. 3 Typically, an infant with recurrent episodes of renal thrombosis, usually preceded by minor infections, develops end-stage renal disease within 10-20 years of diagnosis. 3, 4 DGKE is a lipid kinase that phosphorylates DAG to PA; DAG is produced when PLC hydrolyzes PtdIns(4,5)P₂. 5 DGKE is unique amongst DGKs because its preferred substrate is 38:4-DAG, a form of DAG containing stearoyl (18:0) and arachidonoyl (20:4) moieties. [6] [7] [8] DGKE is highly expressed in glomerular podocytes and endothelial cells (ECs). 3 However, of these two cell types, only the latter actively regulates thrombosis. 9 Based on its enzymatic mode of action, it is generally assumed that DGKE deficiency leads to accumulation of its substrate, DAG, and concomitant depletion of the reaction product, PA. 10 In that context, enhanced DAG-dependent signaling is deemed central to the pathophysiology of DGKE aHUS. 10 While this assumption is eminently reasonable, there are no studies assessing directly how DGKE deficiency impacts the levels of DAG, PA or other related phospholipids in ECs or kidney glomeruli. The high DAG hypothesis thus remains unproven.
To address this issue, we developed a mass spectrometry lipidomics approach to quantify all the relevant lipids from the same sample. We also engineered two novel experimental models of DGKE deficiency: 1) DGKE -/-iHUVEC clones modified using Cas9 genome editing, and 2) BOEC derived from a patient with DGKE aHUS. Our results, which do not support the high DAG hypothesis but So et al. Lipid profiling of DGKE-deficient endothelia instead point to more complex effects on phosphoinositide biosynthesis, will help guide the development of novel therapies for DGKE aHUS, while also providing a unique opportunity to study fatty acyl chain-specific lipid biology.
CONCISE METHODS

DGKE -/immortalized HUVEC (iHUVEC)
We used Cas9 RNA-guided nuclease genome editing coupled with dual single-guide RNAs to generate an EC line devoid of DGKE activity. The cell line used is RF24, an immortalized cell line derived from HUVEC (a generous gift from Dr. Ingbord Klaassen, University of Amsterdam). 11, 12 We used dual Cas9 RNA-guided nuclease genome editing to trigger either a large (14 kb) deletion and/or small indels in the DGKE gene (Supplemental Figure 1) . 13 This approach yielded three clones with biallelic loss-of-function variations by triggering either a macrodeletion within the DGKE gene and/or frameshift mutations. Three wild-type clones were also generated as controls. Cell from passage 4-12 were used for experiments. We used established protocols to measure DGKE mRNA by RT-qPCR 14, 15 and EC cell surface markers by flow cytometry (CD31, CD54, CD105 and CD144). 16 All cell lines were systematically tested for the presence of mycoplasma contamination every year with the MycoAlert PLUS Mycoplasma Detection Kit (cat# LT07-705, Lonza, Basel, CHE).
Human BOEC from a patient with DGKE aHUS
Patient-derived BOEC are complementary to the iHUVEC approach because these cells are not immortalized and they harbor homozygous missense DGKE mutations known to cause disease. We used the established protocol to generate BOEC from a patient with molecularly confirmed diagnosis of DGKE aHUS (BOECDGKE) and an unrelated adult control subject (Supplemental Figure 2 ). 17 All participants signed an informed consent form detailing this procedure. BOECs from passages 4-12 So were used for experiments. DGKE mRNA levels and EC cell surface markers were investigated as described for iHUVEC.
Mass Spectrometry-Based Lipidomics on EC lines
To normalize the lipidomics data, half of a dish with confluent ECs was processed to quantify protein concentration using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) according to the manufacturer's protocol. The other half was used for acidic lipid extraction with TCA precipitation following an established protocol. 18 Lipid analytical internal standards for DAG, PtdIns, PtdInsP₂ and PtdInsP₃ were added to the TCA precipitates (all from Avanti Polar Lipids, Inc). Extracted lipids were dried under a stream of N₂ gas and then stored at -80°C. Prior to analysis, phosphate negative charges on phosphoinositides were neutralized by methylation.
Samples were analyzed with mass spectrometry in the multiple reaction monitoring mode, using electrospray and positive ion mode, as described. 18 Peak areas for acyl-chain specific lipid species and standards were quantified by integrating mass spectrometry curves as previously described. 18 Peak areas were normalized to total protein levels and to the peak area of the corresponding synthetic lipid standard to account for differential loss of samples during lipid extractions and methylation. For analysis of lipid species without a corresponding synthetic lipid standard, the values were normalized to total protein and expressed as normalized peak areas. It is important to note that our study is optimized to confidently assess the levels of 38:4-containing lipids. While levels for the other measurable lipid species are also provided, the level of confidence should be assumed to be lower because of multiple testing issues.
Measurement of Phosphoinositides (PtdIns) Using Radioactive ³H-inositol Labelling
iHUVEC cells were grown as described above except that just before the cells reached confluence, So et al. Lipid profiling of DGKE-deficient endothelia the growth medium was changed to an inositol-free EC medium with endothelial growth supplements (both products from ScienCell). The solution was supplemented with 75 mCi/mL myo-[2-³H(N)] inositol (Perkin Elmer) and 5% dialyzed inositol-free FBS. After 24 hours, adherent cells were scraped and processed following a protocol recently described. 19, 20 Briefly, lipids were extracted after precipitation and de-acylation. ³H-inositol loading was measured with flow scintillation (³H window) before storage at -20°C until ready for further processing. Data for specific phosphatidylinositide species were obtained with high performance liquid chromatography (HPLC) followed by flow scintillation based on their known retention times as described. 19 For each species, we recorded the peak area (total counts), subtracted the background signal, and normalized the resulting data against the parental PtdIns species. Results are expressed as n-fold change in DGKE -/compared to control.
Measuring PtdIns(4,5)P₂ Using Fluorescently Labelled Lipid Binding Probes
Near-confluent iHUVEC were transfected with plasmids encoding the fluorescent PtdIns(4,5)P₂ biosensor PH-PLCδ-GFP. 21 It encodes for the pleckstrin homology (PH) domain of phospholipase C delta (PLCδ) fused to GFP (gift from Dr S. Grinstein). 21 Cells were analyzed by confocal microscopy 24-48 hours post-transfection and after short exposure to the nuclear stain Hoechst® 33342 (Thermo Fisher Scientific). Data were captured and analyzed using Volocity Software (Perkin Elmer, Woodbridge, Canada). The mean GFP fluorescence intensity per pixel was measured in the plasma membrane (PM) and cytosol (cyt); background signal was subtracted from each value. The semiquantitative measure of plasmalemmal PtdIns(4,5)P₂ was quantified as the ratio of PM/Cyt GFP fluorescence.
Statistical Analysis
All data represent three independent experiments unless otherwise indicated. Data is represented as 
RESULTS
Generation of a DGKE-deficient endothelial model
To better understand the pathogenesis of DGKE aHUS, we studied the impact of complete DGKE deficiency on the lipid profile of ECs. We focused our studies on these cells because they have an established role in regulating thrombosis, whereas podocytes do not. 22 To this end, we applied CRISPR/ Cas9 to iHUVEC 11, 12 to generate three DGKE -/clones (Figure 1A-B ). DGKE -/cells have reduced levels of DGKE mRNA and protein, are free of mutations at predicted off-target sites, have normal levels of EC surface markers by flow cytometry, and their wound healing ability is similar to that of control cells (Supplemental Figure 1) .
DGKE-deficient iHUVEC have low PA
Since DGKE phosphorylates DAG to PA, the absence of a functional enzyme may be predicted to cause PA reduction ( Figure 1C) . We compared the lipid composition of wild-type and DGKE -/-iHUVECs by mass spectrometry to validate this prediction. The sum of all measurable PA species was significantly lower in DGKE -/when compared to wild-type ( Figure 1D ). DGKE is known to preferentially phosphorylate DAG decorated with 38:4 fatty acyl chains -stearic acid, 18:0; arachidonic acid, 20:4-to the corresponding PA. A more detailed lipidomic analysis was therefore undertaken to investigate whether this PA species was particularly affected. As expected, we found that 38:4-PA levels were markedly reduced in DGKE -/-iHUVEC ( Figure 1E ). However, PAs decorated with other acyl chain combinations also appeared to be significantly lower in these cells ( Figure 1E) .
These data confirm that DGKE activity is indeed critical to generate 38:4-PA, a finding consistent 
DAG is not elevated in DGKE -/-iHUVEC
The reduced formation of PA observed in the DGKE-deficient cells should, in principle, be accompanied by accumulation of its precursor, DAG ( Figure 1C) . Strikingly, we found the total DAG content to be markedly reduced in DGKE-deficient iHUVEC (Figure 1F) . Detailed mass spectrometric analyses revealed that the decrease was most significant for 38:4-DAG, although other species were also depressed ( Figure 1G) . These unexpected results suggest that the cellular changes accompanying DGKE deficiency are more complex than anticipated.
Generation of patient-derived EC model of DGKE deficiency
The unexpected findings described above may reflect a peculiarity of gene-edited iHUVEC. It was therefore important to validate their occurrence in alternative experimental models of DGKE deficiency. Towards this goal, we generated BOEC 17 from a patient with a novel homozygous DGKE 
38:4-PA is low and 38:4-DAG is not high in BOEC DGKE
We used mass spectrometry to assess if PA reductions were also observed in BOECDGKE.
Detailed analysis of the discrete PA composition showed that these cells had significantly lower 38:4-So et al. Lipid profiling of DGKE-deficient endothelia PA while having elevated levels for nearly all other PA species measured ( Figure 2D) . As a result, total PA was marginally higher when comparing mutant to control BOEC (Figure 2E) .
We then sought to determine if the level of 38:4-DAG in BOECDGKE would be elevated, conforming to the prediction (Figure 1C) , or would instead replicate the unexpected results obtained with DGKE -/-iHUVEC ( Figure 1G ). Similar to the pattern observed for PA in BOECDGKE, we found a trend towards lower 38:4-DAG (p=0.074) accompanied by significant increases in most other DAG species (Figure 2F) . As a result, total DAG levels were significantly elevated in BOECDGKE ( Figure   2G ). PtdIns, the precursor of PtdInsP₂, requires PA, which is in turn generated from DAG by DGK ( Figure   3A ).
We therefore compared the PtdInsP₂ content of wild-type versus DGKE-deficient cells by mass spectrometry, using the two systems described above. Total PtdInsP₂ measurements showed significant differences between wild-type and DGKE-deficient samples in both systems (Figures 3B-D) . As was the case for total DAG, total PtdInsP₂ content was lower in the DGKE -/-iHUVEC when compared to wild-type samples. The situation was reversed for BOECDGKE, with slightly higher PtdInsP₂ content, resembling the findings obtained for DAG ( Figure 2G) . The similarities between systems were greater when individual PtdInsP₂ species were analyzed. The content of 38:4-PtdInsP₂ was reduced in both models of DGKE deficiency (Figures 3E-G) . Moreover, the net increase in PtdInsP₂ content recorded in BOECDGKE was attributable to an elevation in PtdInsP₂ species with the same acyl chain combinations observed for PA and DAG.
Collectively, these results strongly suggest that, by reducing the availability of 38:4-PA, DGKE deficiency alters the PI cycle, preferentially affecting the synthesis of 38:4-PtdInsP₂, the most biologically active form of PtdInsP₂. 28
Reduction in 38:4-PtdInsP₂ is due to low PtdIns(4,5)P₂
Mass spectrometric analyses can quantify the content of PtdInsP₂ with specific acyl chains but cannot distinguish among the three constituent isomers, namely PtdIns(4,5)P₂, PtdIns(3,4)P₂ and PtdIns(3,5)P₂. PtdIns(4,5)P₂ is generally more abundant than the two other species, and is therefore likely to account for the observed changes, but direct demonstration of this assumption was lacking.
Two approaches were used to address this possibility. First we took advantage of the geneticallyencoded biosensor PLCδ-PH-GFP that specifically binds to the headgroup of PtdIns(4,5)P₂. 21 (Figure 4A) , as described for other cell types. 21 The ratio of plasmalemmal-to-cytoplasmic GFP fluorescence was used as a measure of relative PtdIns(4,5)P₂ abundance, thereby accounting for differences in transfection efficiency between cells. When estimated in this fashion, the PtdIns(4,5)P₂ content of all 3 DGKE -/-iHUVEC clones was 20-30% lower than controls (Figure 4B; Supplemental Figure 4 ).
It is challenging to measure PtdIns(3,4)P₂ or PtdIns(3,5)P₂ using fluorescent lipid-binding probes because these species are comparatively scarce in cells. 29, 30 Furthermore, a high-avidity probe for PtdIns (3, 4) P₂ was not available until very recently 31 , and the validity of the only available probe for PtdIns(3,5)P₂ 32 has been questioned. 33 To circumvent these problems, we attempted to fractionate the different PtdInsP₂ isomers by HPLC to resolve the relative abundance. Newly synthesized phosphoinositides were metabolically labeled with [³H]myo-inositol after incubating confluent cells in inositol-free medium. Lipid extracts were deacylated and head-groups were separated by HPLC and detected by flow scintillation.
Because each experiment requires large amounts of [³H]myo-inositol, only a single DGKE -/-iHUVEC clone (KO23) was compared with a control. We found that [³H]myo-inositol uptake was similar between these cell. Reassuringly, newly synthesized PtdIns(4,5)P₂ levels were significantly decreased (by ≈20%) in DGKE -/compared to control iHUVEC (Figure 4B) . Of note, the sum of PtdIns(3,4)P₂ and PtdIns(3,5)P₂, which could not be independently resolved by the chromatographic scheme applied, was higher in DGKE -/cells, although the increase did not attain statistical significance.
This increase is unlikely to be of biological significance since the contribution of PtdIns(3,4)P₂ and PtdIns(3,5)P₂ to the total PtdInsP₂ pool is negligible. Indeed, despite the increase in these two species, the total PtdInsP₂ content -which is dominated by PtdIns(4,5)P₂-was lower in DGKE -/compared to So (Figure 4C) .
Overall, the data from 3 orthogonal methods strongly suggest that at least in iHUVEC, DGKE deficiency causes a significant reduction in PtdInsP₂ levels that is mostly explained by abnormal PtdIns(4,5)P₂ metabolism. This phenomenon is attributable at least in part by changes in 38:4-PtdIns(4,5)P₂ and is seemingly accompanied by a small compensatory increase in PtdIns(3,4)P₂ and PtdIns(3,5)P₂ of unknown physiologic significance.
Impact of DGKE deficiency on PtdIns(3,4,5)P₃
Finally, we sought to determine if the reduced 38:4-PtdInsP₂ found in DGKE -/-iHUVEC translated into lower 38:4-PtdIns(3,4,5)P₃ levels. This would be an important finding because DGKE deficiency would then simultaneously affect two major signaling pathways: one dependent on PLC, and the other on phosphatidylinositol 3-kinase (PI3K; Figure 5A ). We obtained robust and reproducible mass spectrometry lipidomics data even though PtdIns(3,4,5)P₃ is considerably less abundant than PtdInsP₂ in cells in basal state (not serum starved). We found that only 38:4-PtdIns(3,4,5)P₃ levels were significantly lower in DGKE -/-iHUVEC, compared to control cells (Figure 5B) . None of the other species was significantly affected. Using the same approach, we also found trends towards lower 38:4-PtdIns(3,4,5)P₃ levels in BOECDGKE, but this difference was not statistically significant ( Figure 5C) .
In DGKE -/-iHUVEC, the sum of all PtdIns(3,4,5)P₃ isomers was only marginally lower in DGKEdeficient cells (Figure 5D) . However, the difference was significant when newly synthesized PtdIns(3,4,5)P₃ was assessed by HPLC analysis of cells radiolabelled with [³H]myo-inositol ( Figure   5E ).This suggests that the pool of 38:4-PtdIns(3,4,5)P₃, and its precursor 38:4-PtdIns(4,5)P₂, turns over faster than other species. Taken together, these data suggest that reduced 38:4-PtdIns(4,5)P₂ content associated with DGKE deficiency causes a secondary reduction in 38:4-PtdIns(3,4,5)P₃ levels. So 
DISCUSSION
We often presume the root cause of DGKE aHUS to be excessive DAG-dependent signaling (e.g., via protein kinase C (PKC)). 10, 34 However, it is unclear if it elevates DAG in affected tissues of patients. Our findings are inconsistent with this notion. We showed that while 38:4-PA was low in DGKE-deficient cells, the content of 38:4-DAG was not increased concomitantly. We obtained similar results in two distinct experimental models of DGKE deficiency. Instead of the predicted DAG elevation, the salient and most consistent finding was the paucity of 38:4-PtdIns(4,5)P₂ (Figures 3 &   4) . We, therefore, conclude that DGKE is essential for the generation 38:4-PA, which is itself required for the PI cycle to generate and maintain plasmalemmal 38:4-PtdIns(4,5)P₂ levels. We suggest that The PH domain of PLCγ that is instrumental in its recruitment to the membrane, selectively binds PtdIns(3,4,5)P₃ 44 , which is depleted pari passu with PtdIns(4,5)P₂ in DGKE-deficient cells. The activation of PLCδ is similarly regulated, but via the binding of its PH domain to PtdIns(4,5)P₂ itself. 45,
46
Given our results, it is prudent to re-interpret prior studies that assumed that elevated DAG is central to DGKE deficiency. The increased p38 and p44/42 activation observed earlier 34 following DGKE siRNA knockdown in HUVEC may not be attributable to high PKC activity. Accordingly, PKC activity was not increased in these cells. 34 In this context, it will be important to assess if DGKE silencing phenocopies DGKE knockout in terms of 38:4-PtdIns(4,5)P₂ levels, in which case the depletion of this phosphoinositide (or of a metabolite produced therefrom) may explain the altered activity of the two kinases. This is important because the phenotype of siRNA knockdown is not always concordant with that of a gene knockout. 47-49 Lastly, it is noteworthy that our results are in agreement with earlier studies that measured lipid levels in brain extracts 50 and fibroblast cell lines 23 derived from the original Dgke -/and control mice. While we noted no differences in DAG levels, both reports highlighted the reduced PtdInsP₂. Our findings show that therapies aimed at reducing DAG levels are unlikely to benefit patients with DGKE aHUS. We should instead focus efforts on restoring 38:4-PtdIns(4,5)P₂ levels, perhaps with intravenous infusion of the lipid itself or, more likely, of its more membrane-permeant precursors. This could mitigate the predicted effects on the actin cytoskeleton, the suboptimal anti-thrombotic protein levels (via defective exocytosis) or decreased nitric oxide production (via poor response to shear stress). Repurposing glycerol 52, 53 may be an attractive candidate therapy since its uptake and phosphorylation -two key steps in de novo PA synthesis 54 -are markedly increased in Dgke -/cells. 55 The propensity of patients to develop renal thrombosis following minor infections 4 suggests that glomerular lipids help prevent excessive thromboinflammation. 56 Acute dampening of systemic inflammation with immunomodulatory agents could thus provide alternative treatment options. The fluorescence intensity in arbitrary units (AU) was normalized to the highest fluorescence value. B) Estimation of the relative levels of plasma membrane PtdIns(4,5)P 2 after transfection of iHUVEC with a fluorescent PtdIns (4,5)P 2 biosensor (PLCδ-PH-GFP). The ratio of plasma membrane fluorescence-tocytoplasm (PM/Cyt) fluorescence was measured for at least 50 cells in three separate experiments for wild-type or DGKE -/-iHUVEC. Data represent the mean from aggregated data of at least 150 cells per clone, each point being the value of one cell. The ratio was normalized to the average ratio of PM/Cyt fluorescence across three experiments with wild-type cells. Error bars denote standard deviations. Unpaired t-tests were performed to compare wild-type cells to each knockout clone (KO5, KO23, KO24). C) Relative levels of PtdInsP 2 isomers using [ 3 H]myo-inositol metabolic cell labeling followed by liquid scintillation counting of the HPLC eluent. All PtdInsP 2 species measurements were normalized to total PI levels. Values of DGKE -/-iHUVEC are expressed as radioactive counts relative to control iHUVEC counts. The dotted red line indicates the expected values if DGKE -/-iHUVEC have levels similar to control cells. D) "All PtdInsP 2 " data are derived from the sum of radioactive signals of PtdIns(3,4)P 2 , PtdIns(3,5)P 2 and PtdIns(4,5)P 2 . Data represent the mean of 3 independent experiments. The error bars denote standard deviation of the mean. * denotes p<0.05, *** p<0.001 and **** p<0.0001. 
